SUMMARY STAGE 2018
GENERAL CODING INSTRUCTIONS
Published October 2023

Effective with cases diagnosed January 1, 2018 and forward

Prepared by
Data Quality, Analysis and Interpretation Branch
Surveillance Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
U.S. Department of Health and Human Services
Public Health Service
National Institutes of Health

Editors
Jennifer Ruhl, MSHCA, RHIT, CCS, CTR, NCI SEER
Carolyn Callaghan, CTR (SEER Seattle Registry)
Nicki Schussler, BS (IMS)

Suggested Citation: Ruhl JL, Callaghan C, Schussler N (eds.) Summary Stage 2018: Codes and Coding Instructions, National Cancer Institute, Bethesda, MD, 2023
NCI SEER
Peggy Adamo, BS, AAS, RHIT, CTR
Lois Dickie, CTR
Serban Negoita, MD, PhD, CTR

Others
Tiffany Janes, CTR (SEER Seattle Registry)
Denise Harrison, CTR (Trainer Educatory)
Lynn Ries, MS (Consultant)

SEER Registrars
Robin Billet, CTR (SEER Georgia Registry)
Loretta Hutson, CTR (SEER Utah Registry)
Harrine Katz, CTR (SEER New Jersey Registry)
Bobbi Matt, MS, CTR (SEER Iowa Registry)
Mary Mroszcyk, CTR (SEER Massachusetts Registry)
Lisa Orr, CTR (SEER Utah Registry)
Lisa Pareti, CTR (SEER Louisiana Registry)
Cathryn Phillips, CTR (SEER Connecticut Registry)
Sandra Reay, CTR (SEER Utah Registry)
Elizabeth (Liz) Ramirez-Valdez, CTR (SEER New Mexico Registry)
Winny Roshala, CTR (SEER Greater California Registry)
Lori Somers, RN (SEER Iowa Registry)
Virginia Williams, CTR (SEER New Mexico Registry)

Copyright information:
All material in this report may be reproduced or copied without permission, citation as to source, however, is appreciated.
We would also like to give a special thanks to the following individuals at Information Management Services, Inc. (IMS) who provide us with document support and web development.

Suzanne Adams, BS, CTR
  Ginger Carter, BA
Michael Coffey, BS
  Jean Cyr, BA
Bran Handley, BS
Charles May, BS
**Publication History**

The original 2-digit Historic Coding was prepared for the National Cancer Institute End Results Group by an Extent of Disease Advisory Group. While this code had been in use since the early 1950s, it was not printed as a formal document until 1967.

The 1977 Summary Staging Guide was prepared by the Demographic Analysis Section of the National Cancer Institute and was edited by Evelyn M. Shambaugh and Mildred A. Weiss. This manual has been reprinted numerous times in the ensuing years.

The Summary Staging Guide 2000 (SS2000) was a follow-on to the two previous staging versions, Summary Stage 1977 and historic stage. SS2000 updated medical terminology and newer concepts of stage. In order to document the SS2000 changes, footnotes designated terms that changed their stage designation and what they would have been in the two previous versions.
**SUMMARY STAGE**

Summary Stage is the most basic way of categorizing how far a cancer has spread from its point of origin. Historically, Summary Stage has also been called General Stage, California Stage, historic stage, and SEER Stage.

The 2018 version of Summary Stage applies to every site and/or histology combination, including lymphomas and leukemias.

Summary Stage uses all information available in the medical record; in other words, it is a combination of the most precise clinical and pathological documentation of the extent of disease. Many central registries report their data by Summary Stage as the staging categories are broad enough to measure the success of cancer control efforts and other epidemiologic efforts.

There are six main categories in Summary Stage, each of which is discussed in detail. In addition, the main category of regional stage is subcategorized by the method of spread. The code structure is:

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>In situ</td>
</tr>
<tr>
<td>1</td>
<td>Localized only</td>
</tr>
<tr>
<td>2</td>
<td>Regional by direct extension only</td>
</tr>
<tr>
<td>3</td>
<td>Regional lymph nodes only</td>
</tr>
<tr>
<td>4</td>
<td>Regional by BOTH direct extension AND lymph node involvement</td>
</tr>
<tr>
<td>7</td>
<td>Distant site(s)/node(s) involved</td>
</tr>
<tr>
<td>8</td>
<td>Benign/borderline*</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if extension or metastasis (unstaged, unknown, or unspecified) Death certificate only case</td>
</tr>
</tbody>
</table>

*Applicable for the following SS2018 chapters: Brain, CNS Other, Intracranial Gland, Medulloblastoma (new for 2023+)

**Note:** For SS2018, code 5 for “Regional, NOS” can no longer be coded. Code 5 (Regional, NOS) is still applicable for SS2000.
GUIDELINES BY STAGE

Code 0: In situ

*Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information*

1. In situ means “in place”. The technical definition of in situ is the presence of malignant cells within the cell group from which they arose. There is no penetration of the basement membrane of the tissue and no stromal invasion. Generally, a cancer begins in the rapidly dividing cells of the epithelium or lining of an organ and grows from the inside to the outside of the organ. An in-situ cancer fulfills all pathological criteria for malignancy except that it has not invaded the supporting structure of the organ or tissue in which it arose.

   *Note:* If the pathology report indicates an in-situ tumor but there is evidence of positive lymph nodes or distant metastases, code to the regional nodes/distant metastases.

2. An in-situ diagnosis **can only be made microscopically**, because a pathologist must identify the basement membrane and determine that it has not been penetrated. If the basement membrane has been disrupted (in other words, the pathologist describes the tumor as microinvasive, microinvasion), the case is no longer in situ and is at least localized (code 1).

3. **Synonyms for In Situ**
   - Behavior code ‘2’
   - Bowen disease (not reportable for C440-C449)
   - Clark Level I for melanoma (limited to epithelium)
   - Confined to epithelium
   - Hutchinson melanotic freckle, NOS (C44_)
   - Intracystic, noninfiltrating (carcinoma)
   - Intraepidermal, NOS (carcinoma)
   - Intraductal (carcinoma)
   - Intraepithelial neoplasia, Grade III (e.g., AIN III, LIN III, SIN III, VAIN III, VIN III)
   - Intraepithelial, NOS (carcinoma)
   - Involvement up to, but not including the basement membrane
   - Lentigo maligna (C44_)
   - Lobular, noninfiltrating (C50 _) (carcinoma)
   - Noninfiltrating (carcinoma)
   - Non-invasive (carcinoma)
   - No stromal invasion/involvement
   - Papillary, noninfiltrating or intraductal (carcinoma)
   - Precancerous melanosis (C44_)
   - Pre-invasive
   - Queryrat erythroplasia (C50 _)
   - Stage 0 (except Paget’s disease (8540/3) of breast and colon or rectal tumors confined to lamina propria/intramucosa)
4. Organs and tissues that have no epithelial layer cannot be staged as in situ, since they do not have a basement membrane.

5. Code 0 is not applicable for the following Summary Stage chapters/Schema IDs.
   - Bone (00381, 00382, 00383)
   - Brain (00721, 2018-2022), (09721, 2023+)
   - Cervical Lymph Nodes, Occult Head and Neck (00060)
   - CNS Other (00722, 2018-2022), (09722, 2023+)
   - Corpus Sarcoma (00541, 00542)
   - Heart, Mediastinum and Pleura (00422)
   - HemeRetic (00830)
   - Ill-defined other (99999)
   - Kaposi Sarcoma (00458)
   - Lymphoma (00790, 00795)
   - Lymphoma Ocular Adnexa (00710)
   - Medulloblastoma (09724, 2023+)
   - Mycosis Fungoides (00811)
   - Myeloma and Plasma Cell Disorders (00821, 00822)
   - Pleural Mesothelioma (00370)
   - Primary Cutaneous Lymphoma (non-MF and SS) (00812)
   - Retinoblastoma (00680)
   - Retroperitoneum (00440)
   - Soft Tissue (00400, 00410, 00421, 00450)
Code 1: Localized

Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information

1. A localized cancer is defined as
   a. Malignancy limited to the site of origin
   b. Spread no farther than the site of origin in which it started
   c. Infiltration past the basement membrane of the epithelium into parenchyma (the functional part of the organ), but there is no spread beyond the boundaries of the organ

   Note: A tumor can be widely invasive or even show metastases within the organ itself and still be “confined to organ of origin” or localized in Summary Stage.

2. For organs that have definite boundaries (such as prostate, testis, or stomach) or sites where there is a clear line between the organ of origin and the surrounding region (such as breast or bladder), it is usually straightforward to determine if the cancer is localized.
   a. An exception is skin, because it is sometimes difficult to determine where the dermis ends, and subcutaneous tissue begins
   b. For many internal organs, it is difficult to determine whether the tumor is localized without surgery; however, with the increasing sophistication of imaging, it may be possible to determine whether a cancer is localized or regional without surgery

3. It is important to know and recognize the names of different structures within the organ (such as lamina propria, myometrium, muscularis) so that a description of invasion or involvement of these structures will not be interpreted inappropriately, which may lead to over-staging.

4. Because Summary Stage uses both clinical and pathological information, it is important to review and read the pathology and operative report(s) for comments on gross evidence of spread, microscopic extension and metastases, as well as physical exam and diagnostic imaging reports for mention of regional or distant disease.
   a. If any of these reports provides evidence that the cancer has spread beyond the boundaries of the organ of origin, the case is not localized.
   b. If the pathology report, operative report and other investigations show no evidence of spread, the tumor may be assumed to be localized

5. Code 1 is not applicable for the following Summary Stage chapters/Schema IDs.
   • Cervical Lymph Nodes and Unknown Primary (00060)
   • Ill-defined other (99999)
**Regional Stage: Codes 2-4**

There are several codes to describe the different methods of regional spread of tumor.

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Regional by direct extension only</td>
</tr>
<tr>
<td>3</td>
<td>Regional lymph node(s) involved only</td>
</tr>
<tr>
<td>4</td>
<td>Regional by BOTH direct extension AND regional lymph node(s) involved</td>
</tr>
</tbody>
</table>

Clinicians may use some terms differently than cancer registrars. Therefore, it is important to understand the words used to describe the spread of the cancer and how they are used in staging. For example

1. “Local” as in “carcinoma of the stomach with involvement of the local lymph nodes.” Local nodes are the first group of nodes to drain the primary site and often are referred to as “regional” nodes. Unless evidence of distant or regional spread is present, such a case should be staged as regional, lymph node(s) involved only, assign 3.

2. “Metastases” as in “carcinoma of lung with peribronchial lymph node metastases”. Metastases in this sense means involvement by tumor. The name of the involved lymph node will determine whether it is a regional node or distant node. In this case, it would be a regional node. It is important to learn the names of regional nodes for each primary site.
**Code 2: Regional by direct extension only**

*Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information*

1. Regional stage by direct extension is perhaps the broadest category as well as the most difficult to properly identify. The brief definition is direct tumor extension beyond the limits of the site of origin. Although the boundary between localized and regional tumor extension is usually well-identified, the boundary between regional and distant spread is not always clear and can be defined differently by physicians in various specialties.

2. Cancer becomes regional by direct extension when there is potential for spread by more than one vascular supply route. For example, if the tumor goes outside of the wall and invades another organ, it regional by direct extension.

3. The formal (scientific) definition of regional used by surgeons is that area extending from the periphery of an involved organ that lends itself to removal en bloc with a portion of, or an entire organ with outer limits to include at least the first level nodal basin. However, en bloc resection (removal of multiple organs or tissues in one piece at the same time) is not always feasible or may have been shown not to be necessary. For example, many clinical trials have shown that lumpectomy or modified radical mastectomy has equivalent survival to the very disfiguring radical mastectomy for treatment of breast cancer.

4. In contrast, radiation oncologists define the term regional as including any organs or tissues encompassed in the radiation field used to treat the primary site and regional lymph nodes.

5. For primary sites that have “walls” (e.g., colon, rectum), regional by direct extension is invasion through entire wall of organ into surrounding organs and/or adjacent tissues, direct extension or contiguous spread. For those primary sites without defined walls, regional by direct extension is when the tumor has spread beyond the primary site or capsule into adjacent structures.

6. Do NOT use code 2 if there is direct extension and regional nodes positive (see code 4).

7. Code 2 is not applicable for the following Summary Stage chapters/Schema IDs.
   - Cervical Lymph Nodes and Unknown Primary (00060)
   - HemeRetic (00830)
   - Ill-defined other (99999)
   - Myeloma and Plasma Cell Disorders (00821, 00822)
Code 3: Regional lymph nodes only

Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information

1. Regional lymph nodes are listed for each chapter/site.
   a. If a lymph node chain is not listed in code 3, then the following resources can be used to help identify regional lymph nodes:
      i. Appendix I
      ii. Anatomy textbook
      iii. ICD-O manual
      iv. Medical dictionary (synonym)

2. If no preoperative treatment was administered and there is a discrepancy between clinical information and pathological information about the same lymph nodes, pathological information takes precedence. It is not necessary to biopsy every lymph node in the suspicious area to disprove involvement. Use the following priority order:
   a. Pathology report
   b. Imaging
      i. If nodes are determined positive based on imaging and then confirmed to be negative on pathological exam, treat the regional nodes as negative when assigning Summary Stage
   c. Physical exam
      i. If nodes are determined positive based on physical exam and then confirmed to be negative on pathological exam, treat the regional nodes as negative when assigning Summary Stage

3. If the patient receives neoadjuvant (preoperative) systemic therapy (chemotherapy, immunotherapy) or radiation therapy, code the clinical information if that is the most extensive lymph node involvement documented. If the post-neoadjuvant surgery shows more extensive lymph node involvement, code the regional nodes based on the post-neoadjuvant information.

4. For solid tumors, the terms “fixed” or “matted” and “mass in the hilum, mediastinum, retroperitoneum, and/or mesentery” (with no specific information as to tissue involved) are recorded as involvement of lymph nodes.
   a. Other terms, such as “palpable,” “enlarged,” “visible swelling,” “shotty,” or “lymphadenopathy” should be ignored for solid tumors. If these terms are used and there is no treatment to indicate lymph node involvement, treat the case as having no lymph node involvement

5. The terms “homolateral,” “ipsilateral,” and “same side” are used interchangeably.

6. Accessible lymph nodes: For “accessible” lymph nodes that can be observed, palpated, or examined without instruments, such as the regional nodes for the breast, oral cavity, salivary gland, skin, thyroid, and other organs, look for some description of the regional lymph nodes. A statement such as “remainder of examination negative” is sufficient to determine negative regional lymph nodes.

7. Inaccessible lymph nodes: For certain primary sites, regional lymph nodes are not easily examined by palpation, observation, physical examination, or other clinical methods. These are lymph nodes within
body cavities that in most situations cannot be palpated, making them inaccessible. Bladder, colon, corpus uteri, esophagus, kidney, liver, lung, ovary, prostate, and stomach are examples of inaccessible sites (this is not an all-inclusive list). When the tumor is Localized and standard treatment for a localized site is done, it is sufficient to determine negative regional lymph nodes.

8. Involved nodes found during sentinel lymph node procedures are classified as positive regional nodes. 
   a. The sentinel lymph node is the first node to receive lymphatic drainage from a primary tumor
   b. If it contains metastatic tumor, this indicates that other lymph nodes may contain tumor. If it 
      does not contain metastatic tumor, other lymph nodes are not likely to contain tumor. 
      Occasionally there is more than one sentinel lymph node

9. For some chapters, ITCs are counted as positive regional nodes, while other chapters count them as negative. See the individual chapters to determine how to count ITCs.

10. Discontinuous (satellite) tumor deposits (peritumoral nodules) for colon, appendix, rectosigmoid and 
    rectum can occur WITH or WITHOUT regional lymph node involvement. Assign the appropriate code 
    according to guidelines in individual chapters. Tumor nodules in pericolic or perirectal fat without 
    evidence of residual lymph node structures can be one of several aspects of the primary cancer: 
    discontinuous spread, venous invasion with extravascular spread, or a totally replaced lymph node. If 
    there are Tumor Deposits AND node involvement, code only the information on node involvement in 
    Summary Stage.

11. If direct extension of the primary tumor into a regional lymph node is shown, code as involved regional 
    nodes.

12. Any positive unidentified nodes included with the resected primary site specimen are to be coded as 
    “Regional Lymph Nodes, NOS”.

13. If the only indication of positive regional lymph node involvement in the record is the physician’s 
    statement of a positive N category from the TNM staging system or a stage from a site-specific staging 
    system, use that information to code regional lymph node involvement.

14. If a specific chain of lymph nodes is named, but not listed as regional, first determine if the name is 
    synonymous with a listed lymph node. Otherwise, assume distant lymph node(s) are involved.

15. Code 3 is not applicable for the following Summary Stage chapters/Schema IDs. 
    • Brain (00721, 2018-2022), (09721, 2023+)
    • CNS Other (00722, 2018-2022), (09722, 2023+)
    • HemeRetic (00830)
    • Ill-defined other (includes unknown primary site, C809) (99999)
    • Intracranial Gland (00723, 2018-2022), (09723, 2023+)
    • Lymphoma (00790, 00795)
      o Primary Cutaneous Lymphoma (00812) and Ocular Adnexal Lymphoma (00710) have separate 
        chapters from Lymphoma and regional lymph node involvement is assigned in these chapters
    • Medulloblastoma (09724, 2023+)
    • Myeloma Plasma Cell Disorder (00821, 00822)
16. Do NOT use code 3 if there are regional nodes positive AND direct extension (see code 4).
Code 4: Regional by BOTH direct extension AND regional lymph node(s) involved

Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information

1. For tumors that are regional (see definition of code 2) and have regional lymph node involvement (see definition of code 3), use code 4.

2. If there is only localized involvement (see definition of code 1) with regional lymph node involvement, assign code 3.

3. Code 4 is not applicable for the following Summary Stage chapters/Schema IDs
   - Brain (00721, 2018-2022), (09721, 2023+)
   - Cervical Lymph Nodes and Unknown Primary (00060)
   - CNS Other (00722, 2018-2022), (09722, 2023+)
   - HemeRetic (00830)
   - Ill-defined other (includes unknown primary site) (99999)
   - Intracranial Gland (00723, 2018-2022), (09723, 2023+)
   - Lymphoma (00790, 00795)
     - Primary Cutaneous Lymphoma (00812) and Ocular Adnexal Lymphoma (00710) have separate chapters from Lymphoma and regional lymph node involvement is assigned in these chapters
   - Medulloblastoma (09724, 2023+)
   - Myeloma Plasma Cell Disorders (00821, 00822)
Code 7: Distant

*Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information*

1. Distant metastases are tumor cells that have broken away from the primary tumor, have travelled to other parts of the body, and have begun to grow at the new location. Distant stage is also called remote, diffuse, disseminated, metastatic, or secondary disease. The point is that in most cases there is no visible continuous trail of tumor cells involving only the primary site and the distant site.

2. Cancer cells can travel from the primary site in any of four ways.
   a. Extension from primary organ beyond adjacent tissue into next organ; for example, from the lung through the pleura into bone or nerve
   b. Travel in lymph channels beyond the first (regional) drainage area. Tumor cells can be filtered, trapped and begin to grow in any lymph nodes in the body
   c. Hematogenous or blood-borne metastases. Invasion of blood vessels within the primary tumor (veins are more susceptible to invasion than thicker-walled arteries) allows escape of tumor cells or tumor emboli which are transported through the blood stream to another part of the body where it lodges in a capillary or arteriole. At that point, the tumor penetrates the vessel wall and grows back into the surrounding tissue
   d. Spread through fluids in a body cavity
      i. Example: malignant cells rupture the surface of the primary tumor and are released into the thoracic or peritoneal cavity. They float in the fluid and can land and grow on any tissue reached by the fluid
      ii. This type of spread is also called implantation or seeding metastases. Some tumors form large quantities of fluid called ascites that can be removed, but the fluid rapidly re-accumulates. However, the presence of fluid or ascites does not automatically indicate dissemination. There must be cytologic evidence of malignant cells. A subsequent clinical diagnosis should be able to override a negative cytology. Malignant cells in ascites or peritoneal washings may not be distant involvement in some schemas

3. Common sites of distant spread are liver, lung, brain, and bones, but they are not listed specifically for each chapter. These organs receive blood flow from all parts of body and thus are a target for distant metastases. However, if the primary site is adjacent to the liver, lung, brain or bone, it is important to review the Summary Stage chapter for the primary site to assure that the stage is not regional by direct extension.
   a. Example: Liver involvement from a primary in the gallbladder. It is likely that this is regional by direct extension rather than distant stage, since the gallbladder is adjacent to the liver

4. Read the diagnostic imaging reports to determine whether the cancer involves the surface of the secondary organ, which could either be regional by direct (contiguous) extension or distant (if determined to be a discontinuous surface implant). If the tumor is identified growing from one organ onto/through the surface of the secondary organ, then it is contiguous extension. But if the tumor is only found in the parenchyma of the secondary organ well away from the primary organ, then it is discontinuous mets.

5. Hematopoietic, immunoproliferative, and myeloproliferative neoplasms are distant except as noted in the Summary Stage chapter.

6. Code 7 is not applicable for the following Summary Stage chapters/Schema IDs
   - Ill-defined other (99999)
Code 8: Benign/Borderline

1. Code 8 is for Benign/borderline neoplasms. Benign/borderline neoplasms are collected ONLY for the following Summary Stage chapters/Schema IDs
   - Brain (00721, 2018-2022), (09721, 2023+)
   - CNS Other (00722, 2018-2022), (09722, 2023+)
   - Intracranial Gland (00723, 2018-2022), (09723, 2023+)
   - Medulloblastoma (09724, 2023+)

2. If a registry collects other benign/borderline tumors that are not reportable, use code 9 for Summary Stage 2018. Code 8, at this time, will not be allowed for other sites.
**Code 9: Unknown if extension or metastasis (unstaged, unknown or unspecified)**

*Note: ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information*

1. If the primary site is unknown (C809), then Summary Stage must be unknown.

2. Assign 9 very sparingly. If possible, contact the physician to see if there is more information about the case which is not in the record, such as diagnostic studies performed prior to admission or documentation in the physician’s office record.

3. There will be cases for which sufficient evidence is not available to adequately assign a stage. Examples include:
   a. The patient expires before workup is completed
   b. A patient refuses a diagnostic or treatment procedure
   c. There is limited workup due to the patient’s age or a simultaneous comorbid or contraindicating condition
   d. Only a biopsy is done and does not provide enough information to assign stage

4. Code 9 is to be used by default for Death Certificate Only (DCO) cases. Do not use any other code, even for those that may have a default value.
   a. *Example:* Death certificate states cause of death is Acute Myeloid Leukemia (AML). Although Leukemias have a default value of Summary Stage 7, still assign Code 9 for DCOs.
GENERAL INSTRUCTIONS FOR USING THE SUMMARY STAGE 2018 MANUAL

The 2018 Summary Stage Manual chapters consist of a one-digit hierarchical code. In the United States, these chapters will apply to January 1, 2018, diagnoses and forward. It is extremely important to thoroughly read all clinical and pathological documentation, including imaging studies, operative and pathology reports, and the clinician’s narrative descriptions of tumor involvement.

1. Updates to the Summary Stage 2018 manual were based on the AJCC 8th edition. Although the two systems are similar, there are many differences between them. For example, something that is regional in AJCC (recorded in T or N) may be distant in Summary Stage. If a structure or lymph node cannot be found in localized (code 1) or regional (codes 2-4), then review distant (code 7).

2. Summary Stage should include all information available within four months of diagnosis in the absence of disease progression or upon completion of surgery(ies) in first course of treatment, whichever is longer.

3. Summary Stage chapters apply to ALL primary sites and histologies. Most chapters are based on primary site, while some are based on histology alone, or both primary site and histology.

4. For ALL primary sites and histologies, Summary Stage is based on a combined clinical and operative/pathological assessment. Gross observations at surgery are particularly important when all malignant tissue cannot be, or was not, removed.
   a. In the event of a discrepancy between pathology and operative reports concerning excised tissue, priority is given to the pathology report
   b. If either clinical or pathological information is not available, code based on the information that is available
      i. Example: Clinical work up at hospital A. Patient was transferred to hospital B for surgery. Hospital A has no information on the findings from the surgery
         1. Assign Summary Stage based on the clinical information

5. Although Summary Stage is based on all information, the evaluation of the following is still needed to determine the correct Summary Stage
   a. Extent of primary tumor
      i. Tumor size does not affect Summary Stage
      ii. For most schemas, the status of SSDIs does not affect Summary Stage
      iii. If there is no information on the extent of the tumor, but there is known regional lymph node involvement or distant metastasis, code based on those
         1. Default to code 3 when the status of the primary tumor is not known, but there is regional lymph node involvement
         2. Default to code 7 when the status of the primary tumor is not known, but there is distant metastasis
      iv. In situ tumors with nodal or metastatic involvement: In the event of an in-situ tumor with nodal or metastatic involvement, Summary Stage will be 3 (for regional lymph node involvement) or Summary Stage 7 (if mets are involved).
1. **Note:** Behavior would be /3 for these tumors. The primary tumor is in situ; however, there is evidence of an invasive component due to the positive lymph nodes or metastatic involvement

   b. Regional lymph node status
      i. If there is no information on the status of regional lymph nodes, code based on the primary tumor or distant metastasis. The Summary Stage algorithm treats unknown lymph node status as NONE
      ii. For most schemas, the status of SSDIs does not affect Summary Stage
         1. If there are SSDIs that evaluate the status of regional lymph nodes, those SSDIs and Summary Stage should agree
      iii. The number of regional lymph nodes does not affect Summary Stage; however, if Regional Nodes Positive = 01-90, 95, 97, this indicates that regional lymph nodes are involved. Summary Stage must be 3, 4, or 7 and cannot be 0, 1, 2 or 9

   c. Metastatic disease status
      i. If there is no information on distant metastasis, assume there are none

6. Chapter-specific guidelines take precedence over general guidelines. Always read the information pertaining to a specific primary site or histology chapter.

7. Clinical information, such as description of skin involvement for breast cancer and distant lymph nodes for any site, can change the Summary Stage. Be sure to review the clinical information carefully to accurately determine the extent of disease.
   a. If the operative/pathology information disproves the clinical information, use the operative/pathology information

8. When multiple tumors are reported as a single primary, assign the greatest Summary Stage from any tumor.

9. Information for Summary Stage from a surgical resection **after neoadjuvant treatment may be used**, but ONLY if the extent of disease is greater than the pre-treatment clinical findings.
   a. If Clinical information is greater than pathological information, code based on Clinical
   b. If Pathological information is greater than clinical information, code based on Pathological
   c. If either Clinical or Pathological information is missing, code based on the information that is available

10. Disease progression, including metastatic involvement, known to have developed after the initial stage workup, should be excluded when assigning Summary Stage.

11. Autopsy reports are used in Summary Stage just as are pathology reports, applying the same rules for inclusion and exclusion.

12. T, N, M information may be used to assign Summary Stage when it is the only information available.

13. Use the medical record documentation to assign Summary Stage when there is a discrepancy between the T, N, M information and the documentation in the medical record. If you have access to the physician, please query to resolve the discrepancy.
a. When there is doubt that documentation in the medical record is complete, assign Summary Stage corresponding to the physician staging.

14. It is strongly recommended that the assessment of the Summary Stage be documented, as well as the choice of the Summary Stage assignment in a related STAGE text field on the abstract.

15. Death Certificate Only (DCO) cases and unknown primaries are assigned ‘9’ for Summary Stage; do not use any other code, even for those that may have a default value.
   a. *Example:* Death certificate states cause of death is Acute Myeloid Leukemia (AML). Although Leukemias have a default value of Summary Stage 7, still assign Code 9 for DCOs.
GUIDELINES FOR SUMMARY STAGE

For efficient assignment of Summary Stage, here are some additional guidelines. Three of the Summary Stage categories can be ruled out quickly: in situ, distant, and localized.

**Note 1:** These guidelines do not apply to benign/borderline tumors.

**Note 2:** ALWAYS check site-specific SS2018 chapters for exceptions and/or additional information

**In situ**

1. Rule out in situ stage disease. Carcinomas and melanomas are the only types of cancer that can be classified as in situ, since they arise only in organs with a basement membrane. Sarcomas are never described as in situ. A pathologist must examine the primary tissue and state that the tumor is in situ. If the cancer is anything except a carcinoma or melanoma, it cannot be in situ.

2. If there is any evidence of invasion (or extension beyond the basement membrane), nodal involvement or metastatic spread, the case is not in situ even if the pathology report so states.

**Distant**

3. Rule out distant disease. If distant metastases can be documented, there is no need to spend a great deal of time identifying local or regional spread. If distant metastases are recorded on imaging or needle biopsy, the stage is already determined, and the patient does not need to undergo a lot of other tests.

4. Hematopoietic diseases, such as leukemia and multiple myeloma, are disseminated or distant at time of diagnosis.

5. Determine distant spread by reading the operative report for comments about seeding, implants, liver nodules, or other indications of metastases to determine if they are indicators of distant disease for a particular chapter. Read diagnostic reports for references to distant disease.

6. If nodes, organs, or adjacent tissues are not specifically mentioned for the primary site of the cancer in the description of the various staging categories, approximate the location and assign Summary Stage based on the stage listed for organs or tissues in the same anatomic area. If there is no match, assume the involved organ/tissues, nodes in question represents distant disease.

**Localized if not in Situ or Distant above**

7. Rule out that the cancer is “confined to the organ of origin.” For a lesion to be classified as localized, it must not extend beyond the outer limits of the organ, and there must be no evidence of metastases anywhere else.

8. Terms such as “blood vessel invasion” or “perineural lymphatic invasion” do not necessarily indicate that the cancer has spread beyond the primary organ – see specific chapter. If tumor at the primary site has invaded lymph or blood vessels, there is the potential for malignant cells to be transported throughout the body. Minor vessel or lymph-vascular invasion within the primary site is not a determining factor in changing Summary Stage unless there is definite evidence of tumor at distant sites.
**Regional**

9. If in situ, distant, and localized categories have been ruled out, the stage is regional.

10. For tissues, structures, and lymph nodes, assume ipsilateral unless stated to be contralateral or bilateral.

11. For solid tumors, if there are lymph nodes involved with the tumor, the stage is at least regional.

12. Determine whether it is regional by direct extension, regional nodes, or both.

**Unknown if Extension or Metastasis**

13. If there is not enough information in the record to categorize a case, and contacting the physician is not possible or has not resulted in additional information, the case must be recorded as unknown.
HOW TO ASSIGN SUMMARY STAGE

Answers to four basic questions will determine the correct Summary Stage.

1. Where did the cancer start?
   a. In what organ or tissue did the tumor originate?
   b. Is there a specific subsite of the organ involved?
   c. Information about the primary site and histology will usually come from the physical examination, a diagnostic imaging report, the operative report or the pathology report.
   d. Code the primary site and histology according to the rules in the International Classification of Diseases for Oncology, Third Edition; 2018 Solid Tumor Rules; and the Hematopoietic Manual and Database.
   e. In addition to recording this code in the primary site and histology fields on the cancer abstract, this code will be useful later in the staging process.

2. Where did the cancer go?
   a. Once the primary site is known, determine what other organs or structures are involved.
   b. Review the physical examination, diagnostic imaging reports, operative report(s), pathology report(s), and laboratory tests to identify any structures that are involved by cancer cells.
   c. Any of these reports can provide a piece of information that might change the stage.
   d. Note whether there is lymphatic or vascular invasion and/or spread, which organs are involved, and whether there is a single focus or multiple foci of tumor.
   e. It is important to know the names of the substructures within the primary site as well as the names of surrounding organs and structures. Note the names of any tissues that are reported to be involved by cancer cells.

3. How did the cancer spread to the other organ or structure?
   a. Did the cancer spread to the new organ/tissue in a continuous line of tumor cells from the primary site?
   b. If the pathologist can identify a trail of tumor cells from one organ to another, the stage may be regional by direct extension or distant by direct extension.
   c. Did the cancer spread by breaking away from the primary cancer and floating to the new site in the blood stream or body fluids (includes lymph within lymph vessels, blood within blood vessels, fluid outside of vessels such as pleural, pericardial, peritoneal)?
   d. If there is no direct trail of tumor cells from the primary organ to another site, the stage is probably distant.

4. What are the stage and correct code for this cancer?
   a. In the Summary Staging Manual 2018, go to the appropriate chapter that includes the ICD-O primary site and/or histology code identified earlier.
   b. Review the chapter looking for the names of the structures and organs that were reported as involved. If more than one structure or organ is involved, select the highest category that includes an involved structure.
DEFINITIONS OF TERMS USED IN THIS MANUAL

Adjacent connective tissue
These are unnamed tissues that immediately surround an organ or structure containing a primary cancer. Use this category when a tumor has invaded past the outer border (capsule, serosa, or other edge) of the primary organ into the organ’s surrounding supportive structures but has not invaded into larger structures or adjacent organs. The structures considered in ICD-O as connective tissue include the following: adipose tissue; aponeuroses; arteries; blood vessels; bursa; connective tissue, NOS; fascia; fatty tissue; fibrous tissue; ganglia; ligaments; lymphatic channels (not nodes); muscle; nerves (spinal, sympathetic and peripheral); skeletal muscle; subcutaneous tissue; synovia; tendons; tendon sheaths; veins, and vessels, NOS. In general, these tissues do not have specific names. These tissues form the framework of many organs, provide support to hold organs in place, bind tissues and organs together, and serve as storage sites for nutrients.

Adjacent organs/structures
Organs are anatomic structures with specific physiologic functions other than (or in addition to) support and storage. There are two types:
- Unnamed: Contiguous growth into an unnamed organ lying next to the primary is coded to ‘adjacent organs/structures’
- Named: Connective tissues may be large enough to be given a specific name
  - Examples: Blood, cartilage and bone are sometimes considered connective tissues, but in this manual, they would be listed separately
  - Contiguous growth from one organ into an adjacent named structure would be coded to ‘adjacent organs/structures.’ For example, the brachial artery has a name, as does the broad ligament and both are structures

Circulating Tumor Cells (CTCs)
See Isolated Tumor Cells

Contiguous
Directly adjacent; continuously adjoining; without lapse or intervening space; used in reference to regionalized cancers and extent of disease.

Cortex (adjective: cortical)
The external or outer surface layer of an organ, as distinguished from the core, or medulla, of the organ. In some organs, such as the adrenal glands, the cortex has a different function than the medulla.

Discontinuous
Tumors that are not connected; tumors in more than one area with normal tissue between them; often a sign of metastatic disease.

Disseminated Tumor Cells (DTCs)
See Isolated Tumor Cells
**Direct extension**
A term used in staging to indicate contiguous growth of tumor from the primary into an adjacent organ or surrounding tissue.

**Distant**
Refers to cancer that has spread from the original (primary) tumor to distant organs or distant lymph nodes.

**Isolated tumor cells (ITCs), Circulating tumor cells (CTCs), Disseminated tumor cells (DTCs)**
Isolated tumor cells (ITCs) are single tumor cells or small clusters of cells not more than 0.2 mm in greatest extent that can be detected by routine H and E stains or immunohistochemistry. An additional criterion has been proposed to include a cluster of fewer than 200 cells in a single histological cross-section. The same applies to cases with findings suggestive of tumor cells or their components by non-morphological techniques such as flow cytometry or DNA analysis.

ITCs do not typically show evidence of metastatic activity (e.g., proliferation or stromal reaction) or penetration of lymphatic sinus walls.

This definition also refers to circulating tumor cells (CTCs) and disseminated tumor cells (DTCs)

**Localized**
In medicine, describes disease that is limited to a certain part of the body. For example, localized cancer is usually found only in the tissue or organ where it began and has not spread to nearby lymph nodes or to other parts of the body. Some localized cancers can be completely removed by surgery.

**Medulla (adjective: medullary)**
The medulla (central) portion of an organ, in contrast to the outer layer or cortex. It is sometimes called marrow. In some organs, such as bone, the medulla or marrow has a different physiologic role than the cortex.

**Parenchyma**
The parenchyma is the functional portion of an organ, in contrast to its framework or stroma. For example, the parenchyma of the kidney contains all the structures which filter and remove waste products from the blood. In general, malignancies tend to arise in the parenchyma of an organ.

**Regional**
In oncology, describes the body area right around a tumor.

**Stroma**
The stroma are the cells and tissues that support, store nutrients, and maintain viability within an organ. Stroma consists of connective tissue, vessels and nerves, and provides the framework of an organ. In general, spread of tumor to the stroma of an organ is still localized or confined to the organ of origin.
AMBIGUOUS TERMINOLOGY

Most of the time, registrars will find definitive statements of involvement; however, for those situations where involvement is described with non-definitive (ambiguous) terminology, use the guidelines below to interpret and determine the appropriate assignment of Summary Stage 2018.

Determination of the cancer stage is both a subjective and objective assessment by the physician(s) of how far the cancer has spread. When it is not possible to determine the extent of involvement because terminology is ambiguous, look at the documentation that the physician used to make informed decisions on how the patient is being treated. For example, assign Summary Stage 2018 based on involvement when the patient was treated as though adjacent organs or nodes were involved.

Use the following lists to interpret the intent of the clinician ONLY when further documentation is not available and/or there is no specific statement of involvement in the medical record. The physician’s definitions/descriptions and choice of therapy have priority over these lists because individual clinicians may use these terms differently.

**Note 1:** Terminology in the chapter takes priority over this list. Some chapters interpret certain words as involvement, such as ‘encasing’ the carotid artery for a head and neck site or “abutment,” “encases,” or “encasement” for pancreas primaries.

**Note 2:** Use this list only for Summary Stage 2018 or EOD 2018.

**Note 3:** This is not the same list used for determining reportability as published in the SEER manual, Hematopoietic Manual or in Section 1 of the Standards for Oncology Registry Entry (STORE). This is not the same list of ambiguous terminology provided in the Solid Tumors Rules published and maintained by the SEER Program.
Use the following lists as a guide *when no other information is available.*

### Involved

<table>
<thead>
<tr>
<th>Term</th>
<th>Equivalent Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent</td>
<td>Incipient invasion</td>
</tr>
<tr>
<td>Apparent(ly)</td>
<td>Induration</td>
</tr>
<tr>
<td>Appears to</td>
<td>Infringe/infringing</td>
</tr>
<tr>
<td>Comparable with</td>
<td>Into*</td>
</tr>
<tr>
<td>Compatible with</td>
<td>Intrude</td>
</tr>
<tr>
<td>Consistent with</td>
<td>Most likely</td>
</tr>
<tr>
<td>Contiguous/continuous with</td>
<td>Onto*</td>
</tr>
<tr>
<td>Encroaching upon*</td>
<td>Overstep</td>
</tr>
<tr>
<td>Extension to, into, onto, out onto</td>
<td>Presumed</td>
</tr>
<tr>
<td>Features of</td>
<td>Probable</td>
</tr>
<tr>
<td>Fixation to a structure other than primary**</td>
<td>Protruding into (unless encapsulated)</td>
</tr>
<tr>
<td>Fixed to another structure**</td>
<td>Suspected</td>
</tr>
<tr>
<td>Impending perforation of</td>
<td></td>
</tr>
<tr>
<td>Impinging upon</td>
<td>To*</td>
</tr>
<tr>
<td>Impose/imposing on</td>
<td>Up to</td>
</tr>
</tbody>
</table>

### Not Involved

<table>
<thead>
<tr>
<th>Term</th>
<th>Equivalent Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abuts</td>
<td>Extension to without invasion/involvement of</td>
</tr>
<tr>
<td>Approaching</td>
<td>Kiss/kissing</td>
</tr>
<tr>
<td>Approximates</td>
<td>Matted (except for lymph nodes)</td>
</tr>
<tr>
<td>Attached</td>
<td>Possible</td>
</tr>
<tr>
<td>Cannot be excluded/rule out</td>
<td>Questionable</td>
</tr>
<tr>
<td>Efface/effacing/effacement</td>
<td>Reaching</td>
</tr>
<tr>
<td>Encased/encasing</td>
<td>Rule out</td>
</tr>
<tr>
<td>Encompass(ed)</td>
<td>Suggests</td>
</tr>
<tr>
<td>Entrapped</td>
<td>Very close to</td>
</tr>
<tr>
<td>Equivocal</td>
<td>Worrisome</td>
</tr>
</tbody>
</table>

* Interpret as involvement whether the description is clinical or operative/pathological
** Interpret as involvement of other organ or tissue
SUMMARY STAGE 2018 CHAPTERS

The Summary Stage site-specific chapters are based on historical staging, Summary Stage 2000 and the AJCC Staging System. Some of the AJCC Staging System chapters were divided to line up with historical Summary Stage chapters.

<table>
<thead>
<tr>
<th>SS Chapter</th>
<th>Applicable Years</th>
<th>Schema ID Name/Description</th>
<th>Applicable Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adnexa Uterine Other</td>
<td>2018+</td>
<td>00588: Adnexa Uterine Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Adrenal Gland</td>
<td>2018+</td>
<td>00760: Adrenal Gland</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00770: NET Adrenal Gland</td>
<td></td>
</tr>
<tr>
<td>Ampulla Vater</td>
<td>2018+</td>
<td>00270: Ampulla Vater</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00302: Ampulla Vater</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>09210: Anus (2023+)</td>
<td>2023+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09190: Appendix (2023+)</td>
<td>2023+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00320: NET Appendix (2018-2023)</td>
<td>2018-2023</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09320: NET Appendix (2024+)</td>
<td>2024+</td>
</tr>
<tr>
<td>Biliary Other</td>
<td>2018+</td>
<td>00278: Biliary Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Bladder</td>
<td>2018+</td>
<td>00620: Bladder</td>
<td>2018+</td>
</tr>
<tr>
<td>Bone</td>
<td>2018+</td>
<td>00381: Bone Appendicular Skeleton</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00382: Bone Spine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>00383: Bone Pelvis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>09721: Brain (2023+)</td>
<td>2023+</td>
</tr>
<tr>
<td>Breast</td>
<td>2018+</td>
<td>00480: Breast</td>
<td>2018+</td>
</tr>
<tr>
<td>Buccal Mucosa</td>
<td>2018+</td>
<td>00076: Buccal Mucosa</td>
<td>2018+</td>
</tr>
<tr>
<td>Cervical Lymph Nodes and Unknown Primary</td>
<td>2018+</td>
<td>00060: Cervical Lymph Nodes and Unknown Primary Tumor of The Head and Neck</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00528: Cervix Sarcoma (2021+)</td>
<td>2021+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09520: Cervix (2021+)</td>
<td>2021+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09722: CNS Other (2023+)</td>
<td>2023+</td>
</tr>
<tr>
<td>Colon and Rectum</td>
<td>2018+</td>
<td>00200: Colon and Rectum</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00330: NET Colon and Rectum (2018-2023)</td>
<td>2018-2023</td>
</tr>
<tr>
<td></td>
<td></td>
<td>09330: NET Colon and Rectum (2024+)</td>
<td>2024+</td>
</tr>
<tr>
<td>Conjunctiva</td>
<td>2018+</td>
<td>00650: Conjunctiva</td>
<td>2018+</td>
</tr>
<tr>
<td>Corpus Carcinoma and Carcinosarcoma</td>
<td>2018+</td>
<td>00530: Corpus Carcinoma</td>
<td>2018+</td>
</tr>
<tr>
<td>Corpus Sarcoma</td>
<td>2018+</td>
<td>00541: Corpus Sarcoma</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00542: Corpus Adenosarcoma</td>
<td></td>
</tr>
<tr>
<td>Digestive Other</td>
<td>2018+</td>
<td>00288: Digestive Other</td>
<td>2018+</td>
</tr>
<tr>
<td>SS Chapter</td>
<td>Applicable Years</td>
<td>Schema ID Name/Description</td>
<td>Applicable Years</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Endocrine Other</td>
<td>2018+</td>
<td>00778: Endocrine Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Esophagus (including GE junction)</td>
<td>2018+</td>
<td>00161: Esophagus (including GE junction) Squamous</td>
<td>2018+</td>
</tr>
<tr>
<td></td>
<td></td>
<td>00169: Esophagus (including GE junction) (excluding Squamous)</td>
<td></td>
</tr>
<tr>
<td>Extrahepatic Bile Ducts</td>
<td>2018+</td>
<td>00242: Cystic Duct 00250: Bile Ducts Perihilar 00260: Bile Ducts Distal</td>
<td>2018+</td>
</tr>
<tr>
<td>Eye Other</td>
<td>2018+</td>
<td>00718: Eye Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Fallopian Tube</td>
<td>2018+</td>
<td>00553: Fallopian Tube</td>
<td>2018+</td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>2018+</td>
<td>00074: Floor of Mouth</td>
<td>2018+</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>2018+</td>
<td>00241: Gallbladder</td>
<td>2018+</td>
</tr>
<tr>
<td>Genital Female Other</td>
<td>2018+</td>
<td>00559: Genital Female Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Genital Male Other</td>
<td>2018+</td>
<td>00598: Genital Male Other</td>
<td>2018+</td>
</tr>
<tr>
<td>GIST</td>
<td>2018+</td>
<td>00430: GIST</td>
<td>2018+</td>
</tr>
<tr>
<td>Gum</td>
<td>2018+</td>
<td>00073: Gum</td>
<td>2018+</td>
</tr>
<tr>
<td>Heart, Mediastinum and Pleura</td>
<td>2018+</td>
<td>00442: Heart, Mediastinum and Pleura</td>
<td>2018+</td>
</tr>
<tr>
<td>HemeRetic</td>
<td>2018+</td>
<td>00830: HemeRetic</td>
<td>2018+</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>2018+</td>
<td>00112: Hypopharynx</td>
<td>2018+</td>
</tr>
<tr>
<td>Ill-Defined Other</td>
<td>2018+</td>
<td>99999: Ill-Defined Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Intrahepatic Bile Ducts</td>
<td>2018+</td>
<td>00230: Bile Ducts Intrahepatic</td>
<td>2018+</td>
</tr>
<tr>
<td>Kaposi Sarcoma</td>
<td>2018+</td>
<td>00458: Kaposi Sarcoma</td>
<td>2018+</td>
</tr>
<tr>
<td>Kidney Parenchyma</td>
<td>2018+</td>
<td>00600: Kidney Parenchyma</td>
<td>2018+</td>
</tr>
<tr>
<td>Kidney Renal Pelvis</td>
<td>2018+</td>
<td>00610: Kidney Renal Pelvis</td>
<td>2018+</td>
</tr>
<tr>
<td>Lacrimal Gland/Sac</td>
<td>2018+</td>
<td>00690: Lacrimal Gland 00698: Lacrimal Sac</td>
<td>2018+</td>
</tr>
<tr>
<td>Larynx Glottic</td>
<td>2018+</td>
<td>00132: Larynx Glottic</td>
<td>2018+</td>
</tr>
<tr>
<td>Larynx Other</td>
<td>2018+</td>
<td>00130: Larynx Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Larynx SubGlottic</td>
<td>2018+</td>
<td>00133: Larynx SubGlottic</td>
<td>2018+</td>
</tr>
<tr>
<td>Larynx SupraGlottic</td>
<td>2018+</td>
<td>00131: Larynx SupraGlottic</td>
<td>2018+</td>
</tr>
<tr>
<td>Lip</td>
<td>2018+</td>
<td>00071: Lip</td>
<td>2018+</td>
</tr>
<tr>
<td>Liver</td>
<td>2018+</td>
<td>00220: Liver</td>
<td>2018+</td>
</tr>
<tr>
<td>Lung</td>
<td>2018+</td>
<td>00360: Lung</td>
<td>2018+</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>2018+</td>
<td>00790: Lymphoma (excluding CLL/SLL) 00795: Lymphoma-CLL/SLL</td>
<td>2018+</td>
</tr>
<tr>
<td>Lymphoma Ocular Adnexa</td>
<td>2018+</td>
<td>00710: Lymphoma Ocular Adnexa</td>
<td>2018+</td>
</tr>
<tr>
<td>Major Salivary Glands</td>
<td>2018+</td>
<td>00080: Major Salivary Glands</td>
<td>2018+</td>
</tr>
<tr>
<td>Medulloblastoma</td>
<td>2023+</td>
<td>09724: Medulloblastoma</td>
<td>2023+</td>
</tr>
<tr>
<td>SS Chapter</td>
<td>Applicable Years</td>
<td>Schema ID Name/Description</td>
<td>Applicable Years</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Melanoma Conjunctiva</td>
<td>2018+</td>
<td>00660: Melanoma Conjunctiva</td>
<td>2018+</td>
</tr>
<tr>
<td>Melanoma Head and Neck</td>
<td>2018+</td>
<td>00140: Melanoma Head and Neck</td>
<td>2018+</td>
</tr>
<tr>
<td>Melanoma Skin</td>
<td>2018+</td>
<td>00470: Melanoma Skin</td>
<td>2018+</td>
</tr>
<tr>
<td>Melanoma Uvea</td>
<td>2018+</td>
<td>00671: Melanoma Iris 00672: Melanoma Choroid and Ciliary Body</td>
<td>2018+</td>
</tr>
<tr>
<td>Merkel Cell Skin</td>
<td>2018+</td>
<td>00460: Merkel Cell Skin</td>
<td>2018+</td>
</tr>
<tr>
<td>Middle Ear</td>
<td>2018+</td>
<td>00119: Middle Ear</td>
<td>2018+</td>
</tr>
<tr>
<td>Mouth Other</td>
<td>2018+</td>
<td>00077: Mouth Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Mycosis Fungoides</td>
<td>2018+</td>
<td>00811: Mycosis Fungoides and Sézary Syndrome</td>
<td>2018+</td>
</tr>
<tr>
<td>Nasal Cavity and Paranasal Sinuses</td>
<td>2018+</td>
<td>00121: Maxillary Sinus 00122: Nasal Cavity and Ethmoid Sinus</td>
<td>2018+</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>2018+</td>
<td>00090: Nasopharynx</td>
<td>2018+</td>
</tr>
<tr>
<td>Orbit</td>
<td>2018+</td>
<td>00700: Orbital Sarcoma</td>
<td>2018+</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>2018+</td>
<td>00100: Oropharynx HPV-Mediated (p16+) 00111: Oropharynx (p16-)</td>
<td>2018+</td>
</tr>
<tr>
<td>Ovary and Primary Peritoneal Carcinoma</td>
<td>2018+</td>
<td>00551: Ovary 00552: Primary Peritoneal Carcinoma</td>
<td>2018+</td>
</tr>
<tr>
<td>Palate Hard</td>
<td>2018+</td>
<td>00075: Palate Hard</td>
<td>2018+</td>
</tr>
<tr>
<td>Parathyroid</td>
<td>2018+</td>
<td>00750: Parathyroid</td>
<td>2018+</td>
</tr>
<tr>
<td>Penis</td>
<td>2018+</td>
<td>00570: Penis</td>
<td>2018+</td>
</tr>
<tr>
<td>Pharynx Other</td>
<td>2018+</td>
<td>00118: Pharynx Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Placenta</td>
<td>2018+</td>
<td>00560: Placenta</td>
<td>2018+</td>
</tr>
<tr>
<td>Pleural Mesothelioma</td>
<td>2018+</td>
<td>00370: Pleural Mesothelioma</td>
<td>2018+</td>
</tr>
<tr>
<td>Primary Cutaneous Lymphomas: Non-MF/SS</td>
<td>2018+</td>
<td>00812: Primary Cutaneous Lymphomas: Non-MF/SS</td>
<td>2018+</td>
</tr>
<tr>
<td>Prostate</td>
<td>2018+</td>
<td>00580: Prostate</td>
<td>2018+</td>
</tr>
<tr>
<td>Respiratory Other</td>
<td>2018+</td>
<td>00378: Respiratory Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Retinoblastoma</td>
<td>2018+</td>
<td>00680: Retinoblastoma</td>
<td>2018+</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>2018+</td>
<td>00440: Retroperitoneum</td>
<td>2018+</td>
</tr>
<tr>
<td>Sinus Other</td>
<td>2018+</td>
<td>00128: Sinus Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Skin (except Eyelid)</td>
<td>2018+</td>
<td>00150: Cutaneous Carcinoma of Head and Neck 00478: Skin Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Skin Eyelid</td>
<td>2018+</td>
<td>00640: Skin Eyelid</td>
<td>2018+</td>
</tr>
<tr>
<td>SS Chapter</td>
<td>Applicable Years</td>
<td>Schema ID Name/Description</td>
<td>Applicable Years</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Soft Tissue</td>
<td>2018+</td>
<td>00400: Soft Tissue Head and Neck&lt;br&gt;00410: Soft Tissue Trunk and Extremities&lt;br&gt;00421: Soft Tissue Abdomen and Thoracic (excluding Heart, Mediastinum, Pleura)&lt;br&gt;00450: Soft Tissue Rare&lt;br&gt;00459: Soft Tissue Other</td>
<td>2018+</td>
</tr>
<tr>
<td>Stomach</td>
<td>2018+</td>
<td>00170: Stomach&lt;br&gt;00290: NET Stomach (2018-2023)&lt;br&gt;09290: NET Stomach (2024+)&lt;br&gt;</td>
<td>2018+&lt;br&gt;2018-2023&lt;br&gt;2024+</td>
</tr>
<tr>
<td>Testis</td>
<td>2018+</td>
<td>00590: Testis&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Thymus</td>
<td>2018+</td>
<td>00350: Thymus&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Thyroid</td>
<td>2018+</td>
<td>00730: Thyroid&lt;br&gt;00740: Thyroid Medullary&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Tongue Anterior</td>
<td>2018+</td>
<td>00072: Tongue Anterior&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Trachea</td>
<td>2018+</td>
<td>00358: Trachea&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Urethra</td>
<td>2018+</td>
<td>00631: Urethra&lt;br&gt;00633: Urethra-Prostate&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Urinary Other</td>
<td>2018+</td>
<td>00638: Urinary Other&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Vagina</td>
<td>2018+</td>
<td>00510: Vagina&lt;br&gt;</td>
<td>2018+</td>
</tr>
<tr>
<td>Vulva</td>
<td>2018+</td>
<td>00500: Vulva (2018-2023)&lt;br&gt;09500: Vulva (2024+)&lt;br&gt;</td>
<td>2018-2023&lt;br&gt;2024+</td>
</tr>
</tbody>
</table>